vitamin · for back pain
Vitamin K2 MK-4
Helps bone hold onto minerals, which matters for the vertebrae in your spine.
Say that in clinical terms
Activates osteocalcin for bone mineralization, improving vertebral bone density and reducing compression fracture risk.
How strong is the research?
2 papers read, 1 supporting.
Who was studied: Studied in 241 Japanese patients with osteoporosis, mostly in their sixties and seventies.
How much to take
daily
15–45 mg
Primarily studied for vertebral fracture prevention. Take with calcium and vitamin D.
Before you take it
- NIH ODS (FNB/IOM): No Tolerable Upper Intake Level (UL) has been established for vitamin K in any form, including MK-4 (menatetrenone); no adverse effects from high vitamin K intake have been demonstrated in healthy adults.
- Vitamin K2 antagonizes vitamin K antagonist anticoagulants (warfarin, acenocoumarol, phenprocoumon); patients stabilized on these drugs must not begin, stop, or substantially change K2 supplementation without medical supervision, as INR destabilization can cause dangerous thrombotic or hemorrhagic events.
- Bile acid sequestrants (cholestyramine, colestipol) and fat-absorption inhibitors (orlistat) reduce intestinal absorption of fat-soluble vitamin K and may lower K2 status in long-term users.
- Certain antibiotics, particularly cephalosporins, can inhibit gut bacterial vitamin K synthesis; broad-spectrum antibiotic courses may transiently lower vitamin K status.
- Clinical trial evidence for bone effects uses 45 mg/day of pharmaceutical menatetrenone (Glakay, approved in Japan as a drug); typical consumer supplement doses of MK-4 range from 1–15 mg/day, and efficacy data from 45 mg/day trials does not establish equivalent efficacy at lower supplement doses.
When to take it
Best taken: with food
What we make of it
The trial measured fractures and bone density. Back pain was never one of its outcomes.
The detail
The study is real, but the title we recorded is wrong: it is about preventing fractures and holding bone density, not about pain. Back pain was never measured. The claim depends on a chain — denser bone, fewer spinal fractures, less pain — that only applies to people with osteoporosis. And it was done in Japanese patients on a high pharmaceutical dose, which has often failed to reproduce elsewhere.